Vol. 44 (2): 213-214, March – Abril, 2018
DIFFERENCE OF OPINION
Carlos A. R. Sacomani 1, Ricardo Vita Nunes 2
1 Departamento de Urologia, AC Camargo Cancer Center, SP, Brasil; 2 Divisão de Urologia, Universidade de São Paulo, USP, São Paulo, SP, Brasil
Keywords: Lasers; Therapeutics; Prostatic Hyperplasia; Transurethral Resection of Prostate
During the past decades, transurethral resection of the prostate (TURP) has been the gold-standard procedure for surgical treatment of benign prostatic hyperplasia (BPH) and became the second most common surgery in men in the Western world (1). A number of other techniques were developed through the years, trying to replace TURP, including vaporization, microwave thermotherapy, transurethral needle ablation (TUNA) and various types of laser therapies. The rational of looking for new therapies for BPH lies on the intention of delivering the same results with less complications and adequate length of stay at the hospital or even as an outpatient procedure. Indeed, morbidity and mortality following TURP are continuous issues. Reich et al. (2) evaluated 10,654 patients that underwent TURP in state of Bavaria, Germany.